Alternate Delivery of Interferons

  • Deborah A. Eppstein
Part of the NATO ASI Series book series (NSSA, volume 113)


The emergence and mushrooming of recombinant DNA technology and the resultant production of genetically-engineered proteins has, for the first time, made feasible the prospect of utilizing many proteins as therapeutic entities. This is largely due to the potential of producing proteins in greater quantities, while before they were unavailable in sufficient amounts for even sound experimental testing (both in vitro as well as in animal models). Proteins of many classes are included, encompassing lymphokines, monokines, growth promotants and other larger polypeptide hormones, blood coagulation factors, enzymes, etc. In addition, the production of antigens for new vaccines which heretofore were unfeasible is now underway. These new prospects for the widespread use of proteins as therapeutic agents coupled with the necessity of appropriate delivery for such protein therapeutics places renewed emphasis on development of suitable delivery system for proteins.


Herpes Simplex Virus Type Hairy Cell Leukemia Passive Target Muramyl Dipeptide Vulvar Intraepithelial Neoplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison, A.C. and Gregoriadis, G., 1974, Liposomes as immunological adjuvants, Nature, 252:252.CrossRefGoogle Scholar
  2. Amkraut, A.A. and Martins, A.B., 1984, Method for administering immunopotentiator, U.S. Patent 4, 484:923.Google Scholar
  3. Anderson, L.C., Wise, D.L. and Howes, J.F., 1976, An injectable sustained release fertility control system, Contraception, 13:375.CrossRefGoogle Scholar
  4. Androphy, E.J., Dvoretzky, I., Maluish, A.E., Wallace, H.J. and Lowey, D.R., 1984, Response of warts in epidermodysplasia verruciformis to treatment with systemic and intralesional alpha interferon. J. Am. Acad. Dermatol., 11:197.CrossRefGoogle Scholar
  5. Beck, L.R., Cowsar, D.L., Lewis, D.H., Gibson, J.W. and Flowers, C.E., 1979, New long-acting injectable microcapsule contraceptive system, Am. J. Obstet. Gynecol., 135:419.Google Scholar
  6. Beck, L.R., Ramos, R.A., Flowers, CE., Lopez, G.Z., Lewis, D.H. and Cowsar, D.R., 1981, Clinical evaluation of injectable biodegradable contraceptive system, Am. J. Obstet. Gynecol, 140:799.Google Scholar
  7. Borden, E., Hawkins, M., Anderson, S., Schiessel, J., Sielaff, K., DeMets, D., Davis, T., Horning, S., Rosno, S., Merigan, T. and Konrad, M., 1985, Phase I evaluation of a synthetic mutant of Interferon β. Cancer Res. (in press).Google Scholar
  8. Celada, A., Gray, P.W., Rinderknecht, E. and Schreiber, R.D., 1984, Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity, J. Exp. Med., 160:55CrossRefGoogle Scholar
  9. De Palo, G., Stefanon, B., Rilke, R., Pilotti, S. and Ghione, M., 1984, Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with papilloma virus infections. Int. J. Tiss. Reac., 6:523.Google Scholar
  10. De Palo, G., Stefanon, B., Rilke, F., Pilotti, S, and Ghione, M., 1985, Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with viral cytopathic effects, J. Reproduct. Med., 30:404.Google Scholar
  11. Douglas, R.M., Albrecht, J.K., Miles, H.B., Moore, B.W., Read, R., Worswick, D.A., and Woodward, A.J., 1985, Intranasal interferon-α 2 prophylaxis of natural respiratory virus infection, J. Infect. Dis., 151:731.CrossRefGoogle Scholar
  12. Eppstein, D.A., 1982, Altered pharmacologic properties of liposome-associated human interferon-alpha, J. Interferon Res., 2:117.CrossRefGoogle Scholar
  13. Eppstein, D.A., Marsh, Y.V., Fraser-Smith, E.B. and Matthews, T.R., 1985, Potent synergistic inhibition of herpes simplex virus-2 by combination of α, β or γ interferons with DHPG (9-[l,3-dihydroxy-2-propoxy)-methyl]guanine): differences in vitro vs. in vivo, in: “The Biology of the Interferon System 1984”, H. Kirchner and H. Schellekens, eds., Elsevier Science Publishers, Inc., New York.Google Scholar
  14. Eppstein, D.A., Marsh, Y.V., Van der Pas, M.A., Felgner, P.F. and Schreiber, A.B., 1985, Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor, Proc. Natl. Acad. Sci. USA, 82:3688.CrossRefGoogle Scholar
  15. Eppstein, D.A. and StewartII, W.E., 1982, Altered pharmacological properties of liposome-associated human interferon alpha, J. Virol. 41:575.Google Scholar
  16. Farr, B.M., Gwaltney Jr., J.M., Adams, K.F., and Hayden, F.G., 1984, Intranasal interferon-α 2 for prevention of natural rhinovirus colds, Antimicrob. Agents Chemother., 26:31.CrossRefGoogle Scholar
  17. Fidler, I.J., Sone, S., Fogler, W.E. and Barnes, Z.L., 1981, Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide, Proc. Natl. Acad. Sci. USA, 78:1680.CrossRefGoogle Scholar
  18. Fraser-Smith, E.B., Eppstein, D.A., Marsh, Y.V. and Matthews, T.R., 1984a, Enhanced efficacy of the acyclic nucleoside 9-(1,2-dihydroxy-2-propoxymethyl)-guanine in combination with beta-interferon against herpes simplex virus type 2 in mice, Antimicrob. Agents Chemotherap., 25:563.CrossRefGoogle Scholar
  19. Fraser-Smith, E.B., Eppstein, D.A., Marsh, Y.V., and Matthews, T.R., 1984b, Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice, Antimicrob. Agents Chemotherap., 26:937.CrossRefGoogle Scholar
  20. Fraser-Smith, E.B., Eppstein, D.A., Marsh, Y.V. and Matthews, T.R., 1985 Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in combination with gamma interferon against herpes simplex virus type 2 in mice, Antiviral Research, 5:137.CrossRefGoogle Scholar
  21. Geffen, J.R., Klein, R.J., and Friedman-Kien, A.E., 1984, Intralesional administration of large doses of human leukocyte interferon for the treatment of condylomata acuminata, J. Infect. Dis., 150:612.CrossRefGoogle Scholar
  22. Kent, J.S., Sanders, L.M., McRae, G.I., Vickery, B.H., Tice, T.R. and Lewis, D.H., 1982, In-vivo controlled release of an LHRH analog from injected polymeric microcapsules, Contracept. Deliv. syst., 3:58.Google Scholar
  23. Maxwell, B.L., Talpaz, M., and Gutterman, J.U., 1985, Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN-α) therapy, Int. J. Cancer., 36:23.CrossRefGoogle Scholar
  24. Miescher-Granger, S., Hochkeppel, H.K., Braun, D.G. and Alkan, S.S., 1985, Biological activities of human recombinant interferon α/β targeted by anti-Epstein-Barr virus monoclonal antibodies, FEBS Lett. 179:29.CrossRefGoogle Scholar
  25. Niimura, M., 1983, Intralesional human fibroblast interferon in common warts, J. Dermatolog., 10:217.Google Scholar
  26. Pelham, J.M., Flannery, G.R., Gray, J.D., Pimm, M.V., and Baldwin, R.W., 1983, Interferon conjugation to human osteogenic sarcoma monoclonal antibody, Cancer Immunol. Immunother., 15:210.CrossRefGoogle Scholar
  27. Queseda, J.R., Reuben, J., Manning, J.T. and Gutterman, J.U., 1984, Alpha interferon for induction of remission in hairy-cell leukemia, New Engl. J. Med., 310:15.CrossRefGoogle Scholar
  28. Quesada, J.R., Swanson, D.Ä., and Gutterman, J.U., 1985, Phase II study of interferon-alpha in metastatic renal carcinoma: a progress report, J. Clin. Oncol., 3:1086.Google Scholar
  29. Sanders, L.M., Kent, J.S., McRae, G.I., Vickery, B.H., Tice, T.R., and Lewis, D.H., 1984, Controlled release of a luteinizing hormone-releasing hormone analogue from poly (d, 1-lactide-co-glycolide)-microspheres, J. Pharmaceut. Sci., 73:1294.CrossRefGoogle Scholar
  30. Schonfeld, A., Schattner, A., Crespi, M., Levavi, H., Shoham, J., Nitke, S., Wallach, D., Hahn, T., Yarden, O., Doerner, T., and Revel, M., 1984. Intramuscular human interferon-β injections in treatment of condylomata acuminata, Lancet, 1:1038.CrossRefGoogle Scholar
  31. StewartII, W.E., 1979, “The Interferon System,” Springer-Verlag, New York.Google Scholar
  32. Vesterinen, E., Meyer, B., Purola, E., and Cantell, K., 1984, Treatment of vaginal flat condyloma with interferon cream, Lancet, 1:157.CrossRefGoogle Scholar
  33. Yolles, S. and Morton, D.F., 1978, Timed-release depot for anti-cancer agents, Acta Pharm. Svec., 15:382.Google Scholar
  34. Yoshikawa, H., Takada, K., Muranishi, S., Yu-ichiro, S. and Naruse, N., 1984, A method to potentiate enteral absorption of interferon and selective delivery into lymphatics, J. Pharm. Dyn., 7:59.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Deborah A. Eppstein
    • 1
  1. 1.Syntex ReserachPalo AltoUSA

Personalised recommendations